Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma

Song, Byeong Geun; Choi, Sung C.; Goh, Myung Ji; Kang, Wonseok; Sinn, Dong Hyun; Gwak, Geum Youn; Paik, Yong–Han; Choi, Moon Seok; Lee, Joon Hyeok; Paik, Seung Woon

doi:10.1016/j.jhepr.2023.100810

Cited by 8 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When fat accumulates excessively within the liver, exceeding 5% of its weight, it is defined as fatty liver. , Fatty liver is divided into two major types: one is an alcoholic fatty liver disease (AFLD), known for its association with prolonged and immoderate alcohol intake. The second type is a metabolic dysfunction associated fatty liver disease (MAFLD), linked to diverse factors including stress, obesity, genetic susceptibility, and metabolic syndrome. − The presence of fatty liver disease is linked to an elevated risk of negative consequences, encompassing liver-related health issues, cardiovascular ailments, and mortality. − As depicted in Figure a, there is a 15% to 20% probability for individuals with MAFLD to develop into metabolic dysfunction-associated steatohepatitis (MASH). In approximately 10% to 20% of instances involving MASH, there is a potential for subsequent progression into cirrhosis, and in more severe cases, the development of HCC may also occur. , …”

Section: Types Of Liver Diseasesmentioning

confidence: 99%

Emerging mRNA Technology for Liver Disease Therapy

Wang,

Fang,

Luo

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Liver diseases have consistently posed substantial challenges to global health. It is crucial to find innovative methods to effectively prevent and treat these diseases. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases. In this review, we start by providing a detailed introduction to the mRNA technology. Afterward, we highlight types of liver diseases, discussing their causes, risks, and common therapeutic strategies. Additionally, we summarize the latest advancements in mRNA technology for the treatment of liver diseases. This includes systems based on hepatocyte growth factor, hepatitis B virus antibody, left−right determination factor 1, human hepatocyte nuclear factor α, interleukin-12, methylmalonyl-coenzyme A mutase, etc. Lastly, we provide an outlook on the potential of mRNA technology for the treatment of liver diseases, while also highlighting the various technical challenges that need to be addressed. Despite these difficulties, mRNA-based therapeutic strategies may change traditional treatment methods, bringing hope to patients with liver diseases.

show abstract

Section: Types Of Liver Diseasesmentioning

confidence: 99%

Emerging mRNA Technology for Liver Disease Therapy

Wang,

Fang,

Luo

et al. 2024

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Moreover, when compared to NAFLD, MAFLD is better recognized in patients with advanced liver fibrosis [33]. The major changes are due to the inclusion of individuals with significant alcohol intake or chronic viral hepatitis in the MAFLD criteria who have been excluded in the NAFLD criteria, and the exclusion of individuals with fatty liver without metabolic abnormality who have been included in the NAFLD criteria [34]. Recently, both MAFLD and NAFLD have been associated with an increased risk of HCC for individuals without other chronic liver diseases [34].…”

Section: Nafld and Reckmentioning

confidence: 99%

“…The major changes are due to the inclusion of individuals with significant alcohol intake or chronic viral hepatitis in the MAFLD criteria who have been excluded in the NAFLD criteria, and the exclusion of individuals with fatty liver without metabolic abnormality who have been included in the NAFLD criteria [34]. Recently, both MAFLD and NAFLD have been associated with an increased risk of HCC for individuals without other chronic liver diseases [34]. NAFLD/MAFLD progression to NASH/metabolic-associated steatohepatitis (NASH/MASH) is due to intrahepatic accumulation of toxic lipids involved in inflammation and oxidative stress [33].…”

Section: Nafld and Reckmentioning

confidence: 99%

See 1 more Smart Citation

Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries

Palladini,

Di Pasqua,

Croce

et al. 2023

IJMS

View full text Add to dashboard Cite

The reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a membrane-anchored glycoprotein, negatively regulates various membrane proteins involved in the tissue governing extracellular matrix (ECM) remodeling such as metalloproteases (MMPs) and the sheddases ADAM10 and ADAM17. The significance of the present review is to summarize the current understanding of the pathophysiological role of RECK, a newly discovered signaling pathway associated with different liver injuries. Specifically, this review analyzes published data on the downregulation of RECK expression in hepatic ischemia/reperfusion (I/R) injury, liver-related cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), as well as in the progression of nonalcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). In addition, this review discusses the regulation of RECK by inducers, such as FXR agonists. The RECK protein has also been suggested as a potential diagnostic and prognostic marker for liver injury or as a biomarker with predictive value for drug treatment efficacy.

show abstract

“…As the most common primary liver cancer, HCC highlights the third major cause of cancer-related death globally, including all types of cancers [2], with five-year survival rates of 25.9-41.7% for early-stage, 5.9% for intermediatestage, and 0.2-0.4% for advanced-stage HCC [3]. HCC is associated with various liver diseases, such as chronic viral hepatitis [4], liver cirrhosis [5], metabolic dysfunctionassociated steatotic liver disease [6], and alcoholic steatohepatitis [7].…”

Section: Introductionmentioning

confidence: 99%

Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies

Zarlashat,

Mushtaq,

Pham

et al. 2024

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and a significant global health burden, with increasing incidence rates and limited treatment options. Immunotherapy has become a promising approach due to its ability to affect the immune microenvironment and promote antitumor responses. The immune microenvironment performs an essential role in both the progression and the development of HCC, with different characteristics based on specific immune cells and etiological factors. Immune checkpoint inhibitors, including programmed death-1/programmed death-ligand 1 inhibitors (pembrolizumab, nivolumab, and durvalumab) and cytotoxic T lymphocyte antigen-4 inhibitors (tremelimumab and ipilimumab), have the potential to treat advanced HCC and overcome adverse effects, such as liver failure and chemoresistance. Phase II and phase III clinical trials highlight the efficacy of pembrolizumab and nivolumab, respectively, in advanced HCC patients, as demonstrated by their positive effects on overall survival and progression-free survival. Tremelimumab has exhibited modest response rates, though it does possess antiviral activity. Thus, it is still being investigated in ongoing clinical trials. Combination therapies with multiple drugs have demonstrated potential benefits in terms of survival and tumor response rates, improving patient outcomes compared to monotherapy, especially for advanced-stage HCC. This review addresses the clinical trials of immunotherapies for early-, intermediate-, and advanced-stage HCC. Additionally, it highlights how combination therapy can significantly enhance overall survival, progression-free survival, and objective response rate in advanced-stage HCC, where treatment options are limited.

show abstract

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma

Cited by 8 publications

References 42 publications

Emerging mRNA Technology for Liver Disease Therapy

Emerging mRNA Technology for Liver Disease Therapy

Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries

Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies

Contact Info

Product

Resources

About